Hong Kong's securities regulator has ordered the suspension of trading in shares of Cloudbreak Pharma (02592.HK), citing serious concerns that the company's initial public offering may have been artificially manipulated to create a false impression of share demand. The suspension took effect at 9:00 am on September 10, with the stock last trading at HK$1.19 — representing a cumulative decline of approximately 88% from its July 2025 listing price of HK$10.10 per share.
The company, founded in 2015 and focused on innovative ophthalmic drugs, had to file four times before successfully listing on the Hong Kong Stock Exchange. It broke its issue price on the very first trading day and now faces an uncertain future amid the regulatory probe.
Company Background: Who Is Cloudbreak Pharma?
Cloudbreak Pharma Inc. is a clinical-stage biotechnology company specializing in ophthalmic treatments. Its core pipeline includes CBT-001 for pterygium and CBT-009 for juvenile myopia, alongside other candidates such as CBT-004 and CBT-006. The company made three unsuccessful listing attempts on November 30, 2023, May 31, 2024, and December 2, 2024, before its fourth attempt from June 24-27, 2025 succeeded. It officially listed on the Hong Kong Stock Exchange's main board on July 3, 2025, offering 60.58 million shares at HK$10.10 each.
China Construction Bank International and Huatai International served as joint sponsors, with UBS having been involved during earlier filing stages. Cornerstone investors included Rich Horizon Holdings, wholly owned by Hikvision founder Gong Hongjia, which subscribed for US$20 million, and Reynold Lemkins Group, which subscribed for US$2.8 million — together accounting for approximately 29.25% of the offering shares. Chairman Ni Jinsong, a US citizen who graduated from Nanjing University with a chemistry degree in 1989, leads the company. The pre-suspension market capitalization stood at approximately HK$1.1 billion.
Cornerstone Investor Spotlight: Who Is Gong Hongjia?
Among the two cornerstone investors, the larger contributor was Rich Horizon Holdings, wholly owned by Gong Hongjia, often described as "China's most successful angel investor." His US$20 million subscription represented the vast majority of the US$22.8 million total cornerstone investment. Gong, born in 1965 and a Hong Kong permanent resident, earned his engineering degree from Huazhong University of Science and Technology. His most famous investment came in November 2001 when he invested RMB 2.45 million for a 49% stake in what would become Hikvision, serving as director and vice chairman. Following Hikvision's 2010 listing, media reports described the return on this investment as exceeding 25,000 times.
Various media outlets reported his personal wealth at approximately RMB 89 billion in 2021-2022 reports, with an earlier 2020 report citing RMB 67 billion — though these figures reflect different reporting periods and methodologies. In November 2019, Gong and Hikvision's general manager Hu Yangzhong were placed under investigation by the securities regulator for information disclosure violations. In March 2020, the regulator determined they had failed to report financing arrangements provided to others during share transactions, issuing warning letters and recording the matter in the securities market integrity archive. His broader investment portfolio spans at least seven listed companies, including Fullhan Micro, Union Optech, Zhongyuan Union Cell, GenScript Biotech, VeriSilicon, and Zero2IPO, with primary investment vehicles including Rich Horizon Holdings and Shenzhen Jiaduogu Investment Management. He is also a limited partner in Sequoia Capital China, IDG Capital, and Hillhouse Capital.
Public information shows his connection to Cloudbreak Pharma was solely as a cornerstone investor in this IPO. No public records indicate he held shares or board positions prior to the listing. The wealth figures and investment details are compiled from various historical media reports with differing measurement standards and timelines, and no independent verification of original shareholding filings has been conducted. Furthermore, no public information links the 2019 regulatory record to the current Cloudbreak matter.
Key Concerns: Subscription Structure and Trading Suspension
The Securities and Futures Commission's suspension directive was issued under Section 8(1) of the Securities and Futures (Securities Market Listing) Rules, with the investigation conducted under Section 182(1) of the Securities and Futures Ordinance. These provisions apply when documents published by a listed company — including prospectuses, circulars, or introductory documents — contain information that is false, incomplete, or misleading in material respects, or when announcements or statements relating to company affairs present similar issues. The SFC stated that its investigation remains ongoing and declined further comment.
According to allocation results verified by Daily Economic News, the public offering portion received subscriptions of 78.78 times the available shares, while the international placement to institutional investors attracted only 0.89 times — meaning it was undersubscribed. The original allocation was 90% international and 10% public offering. Following the undersubscribed international tranche, the company reallocated shares, reducing the international portion to 80% and increasing the public offering to 20%. Several Hong Kong media outlets noted this operation complies with exchange listing rules and did not trigger the standard automatic clawback mechanism — which would typically increase the public offering portion proportionally when retail demand is strong. In this case, however, the adjustment moved shares from the undersubscribed institutional tranche to the retail portion.
Hong Kong media reported that dark pool trading ahead of the listing briefly surged nearly 40%, yet the stock price weakened consistently after the official debut. Even the stage-high of HK$9.58 reached in December 2025 remained below the HK$10.10 issue price. The stark contrast between enthusiastic retail subscription and institutional demand below 0.9 times presents a classic profile of what regulators have recently identified as a "false impression of demand" in Hong Kong's IPO market. Daily Economic News also reported that a person close to the IPO described tense internal atmosphere during the weekend after the subscription period, suggesting management lacked confidence in the outcome, though this account has not been confirmed by the company.
Share Price History and Financial Performance
The stock opened below its issue price on its first trading day, at one point falling more than 40%, with closing market value in the range of HK$5.2-5.9 billion depending on the measurement point. By November 17, 2025, the stock closed at HK$4.33, down 57.13% from the issue price. After five consecutive gaining sessions, it reached HK$7.26 on November 27, 2025. The December 2025 stage-high of HK$9.58 still failed to reach the issue price. On January 2, 2026, cornerstone investor Rich Horizon Holdings voluntarily extended its lock-up period by six months to July 2, just ahead of the original expiry date. On January 5, 2026, when the other cornerstone investor Reynold Lemkins' lock-up expired, the stock fell 8.94% to HK$3.36. The same day, the company disclosed that its Guangzhou subsidiary's bank account had been subject to judicial preservation by the Guangzhou Huangpu District People's Court at Cedar Wealth's request, with an account balance of approximately RMB 2.55 million.
The voluntary extension of the lock-up period by one cornerstone investor close to the expiry date was an unusual signal — such extensions typically suggest either an attempt to avoid sell-off pressure or a cautious view on near-term share price prospects, though the company has not publicly explained the motivation. Regarding the bank account preservation, no public information currently links this matter to the IPO manipulation investigation, and it is presented here solely as a separately disclosed corporate governance item.
The company's financial position shows persistent losses with no commercialized products. Between 2022 and 2026, the company recorded zero or minimal revenue — approximately RMB 10 million in 2024 from a license agreement with Santen Pharmaceutical — while research and development expenses ranged from approximately US$15.29 million in 2022 to US$37.95 million in 2024. Net losses widened from approximately US$66.8 million in 2022 to US$99.1 million in 2024, with 2025 full-year losses of approximately US$67.7 million. In the first half of 2026, the company swung to a loss of approximately US$48.0 million, with operating losses of approximately US$48.3 million representing a 43.59% year-on-year increase and a loss per share of US$0.06, compared to a profit of US$5.2 million in the same period the previous year. The interim results announcement reported other income of US$44,000, primarily from government subsidies for research activities from Suzhou local government. As of end-2024, the company held cash of US$34.86 million with no other borrowings. Since 2018, the company has completed four financing rounds totaling approximately US$144 million, with the final round's post-investment valuation around HK$3.66 billion.
Industry Context: From Hontex to IPO Subscription Irregularities
The SFC's action to suspend trading over suspected IPO manipulation has precedent. On March 30, 2010, Fujian-based shoemaker Hontex International was ordered suspended and subsequently found to have a prospectus containing false and misleading data. Hong Kong's High Court, acting under Section 213 of the Securities and Futures Ordinance, ordered the company to repurchase shares from approximately 7,700 public shareholders at HK$2.06 per share — the suspension price — totaling HK$1.03 billion. This was the first time the SFC had achieved a compulsory buyback under this provision, described by then-SFC CEO Ashley Alder as a significant milestone in protecting investors from misconduct.
It is important to note that Hontex and the current Cloudbreak case differ in the nature of allegations, investigation stage, and applicable provisions. Hontex ultimately was found to have falsified prospectus data, while Cloudbreak currently remains at the "suspension and investigation" stage with no finding of wrongdoing. The Hontex case serves merely as historical procedural reference, not a prediction of outcome. More notably, Bloomberg reported in July 2026 that the SFC has identified book-building and IPO share allocation as the next key enforcement focus. Regulators have found that some new listings exhibit patterns of unfair share allocation, including subscription orders allegedly funded by parties connected to the issuer or major shareholders themselves, artificially inflating public demand. The SFC has notified the involved investment banks and required them to develop remediation plans. While no public evidence directly links this regulatory trend to the Cloudbreak case, the timing aligns with intensified scrutiny of subscription manipulation in Hong Kong's IPO market.
Final Observations
The most striking aspect of the Cloudbreak case is not the share price decline — biotech stocks breaking below issue price upon listing is not uncommon in Hong Kong — but rather the structure of the subscription demand itself. The combination of 78.78 times oversubscription in the public offering alongside institutional subscription below 90% presents exactly the profile regulators have flagged as potentially indicating artificially created demand. When institutional investors voting with real capital decline to participate while retail demand runs unusually hot, the gap warrants scrutiny. The company's decision to reallocate shares from the international tranche to the public offering, rather than triggering the standard clawback mechanism, has been described by media as compliant with exchange rules — yet the motivation behind such operations naturally receives greater scrutiny in the current regulatory environment. The voluntary lock-up extension by a cornerstone investor close to expiry also appears noteworthy, as capital willing to remain locked conveys different signals than funds rushing to exit. For Cloudbreak Pharma, however, the more pressing reality is fundamental: this is a clinical-stage pharmaceutical company with no commercialized products and years of net losses, having swung back to losses in the first half of 2026. The sustainability of its cash position may prove more urgent than the suspension investigation itself. While regulatory findings remain forthcoming, the market has already delivered its verdict through an 88% cumulative decline.
Source Notes and Disclaimers
Verified information includes the SFC suspension directive and its legal basis, subscription and allocation results, offering ratio adjustments, historical share price trajectory, and annual financial data, all drawn from media reports of official announcements and public disclosure documents. Single-party claims subject to confirmation include the anonymous source's account of management's lack of confidence during the subscription period, which has not been company-confirmed, and the comparability of the Hontex case serving only as historical procedural reference. Analytical interpretations regarding connections between the subscription structure and potential demand manipulation, as well as the motivation behind the cornerstone investor's lock-up extension, represent observational analysis based on public information and do not constitute findings of wrongdoing. All information in this article derives from public disclosure documents and media reports, serves as market observation only, and does not constitute investment advice.